Pharma channel feed

Like Gilead, Ab­b­Vie gets its ten­ta­cles in­to pact with Ten­tar­ix

Last year
Startups
Deals

Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Last year
R&D
Coronavirus

Unit­ed Ther­a­peu­tics sues FDA over han­dling of Liq­uidia’s new drug ap­pli­ca­tion for tre­pros­tinil

Last year
FDA+
Law

House De­moc­rats re­it­er­ate call for FDA to work on clin­i­cal di­ver­si­ty ac­tion plans

Last year
FDA+

First Keytru­da biosim­i­lars move in­to clin­i­cal tri­als as Mer­ck push­es ahead with new for­mu­la­tion

Last year

Is a mail­box an of­fice? Not ac­cord­ing to the US' bank­rupt­cy ar­gu­ment against Sor­ren­to Ther­a­peu­tics

Last year
Law

J&J so­cial me­dia pro­gram aims to add more di­verse voic­es in lung can­cer ad­vo­ca­cy

Last year
Marketing

Af­ter No­var­tis’ Adakveo was pulled in Eu­rope, the UK fol­lows suit 

Last year

Emer­gent calls on new CEO Joe Pa­pa to lead turn­around fol­low­ing pan­dem­ic stum­bles

Last year
People

Vi­iV's long-act­ing Cabe­nu­va beats out dai­ly oral HIV treat­ments in PhI­II

Last year
R&D

Up­dat­ed: NJ court says drug­mak­ers can co­or­di­nate their le­gal fight against the gov­ern­men­t's price ne­go­ti­a­tions

Last year
Law

Bay­er plans 95% cut to div­i­dend as part of CEO Bill An­der­son­'s turn­around project

Last year

Rick Gon­za­lez de­fend­ed Ab­b­Vie's em­pire. The next CEO will have to build a new one be­yond Hu­mi­ra

Last year
People

Mar­ket­ingRx roundup: Op­di­vo, Veozah on Peo­ple’s Choice Awards; AZ pub­lish­es new sus­tain­abil­i­ty re­port

Last year
Marketing

Take­da read­ies next phase in cor­po­rate and R&D cam­paign to help boost US pro­file

Last year
Marketing

Ab­b­Vie CEO Richard Gon­za­lez to re­tire Ju­ly 1 with Hu­mi­ra tran­si­tion un­der­way

Last year
People

The $100 bil­lion club gets a shake­up, dri­ven by biotech’s new blue-chip names

Last year
R&D

FDA ap­proves Io­vance's cell ther­a­py for melanoma, the first treat­ment based on tu­mor-in­fil­trat­ing lym­pho­cytes

Last year
Cell/Gene Tx
FDA+

Organon's Hu­mi­ra biosim­i­lar gets ex­clu­sive spot on VA for­mu­la­ry

Last year
FDA+

EMA pre­pares for changes to non-in­fe­ri­or­i­ty, equiv­a­lence study guid­ance

Last year
FDA+

FDA ex­pands la­bel for No­var­tis and Roche's block­buster, con­verts EMD Serono's NSCLC drug to full ap­proval

Last year
FDA+

As­traZeneca asks fed­er­al judge to de­cide in its fa­vor in drug price ne­go­ti­a­tions law­suit

Last year
Law

FDA goes af­ter web­sites mar­ket­ing 'u­nap­proved' semaglu­tide, tirzepatide

Last year
FDA+

Es­hoo calls out FDA for miss­ing dead­line on di­ver­si­ty ac­tion plan guid­ance

Last year
FDA+
First page Previous page 72737475767778 Next page Last page
A service from the Financial Times